Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results

Nicole DeFeudis

Editor

Several months after a name change and major restructuring, Kuur Therapeutics has offered an early glimpse at results from a small number of patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results

Nicole DeFeudis

Editor

Sign up to read this article for free.

After stock slides, Amgen addresses bone density talk on obesity drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Months af­ter a ma­jor re­brand­ing around CAR-NKT cells, Ku­ur Ther­a­peu­tics is of­fer­ing a peek at ear­ly re­sults

Nicole DeFeudis

Editor

Sign up to read this article for free.

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results

After stock slides, Amgen addresses bone density talk on obesity drug

J&J takes 340B fight with federal government to court

'Expertise is a real thing': FDA commissioner warns of political risk to agency

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?